New Crestor data in African-American patients with high cholesterol
NEW ORLEANS (November 9, 2004) -- New data presented today at the American Heart Association's Annual Scientific Sessions showed that AstraZeneca's CRESTOR (rosuvastatin calcium) at 10 and 20 mg reduced LDL-C or "bad" cholesterol by 37 and 46 percent, compared to 32 and 39 percent at similar doses with atorvastatin in African-American patients. CRESTOR also brought more patients in this study to...Outstanding efficacy of Crestor (TM) in treating range of patient populations at risk of CVD
London, UK, 25 October 2004. New data presented today from several studies involving more than 5,000 patients provide further evidence of the outstanding efficacy of CRESTOR ...... Results from five studies (DISCOVERY, COMETS, MERCURY I, URANUS, RADAR) presented at the XV International Symposium on Drugs Affecting Lipid Metabolism (DALM) demonstrate that CRESTOR is sup...CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome
London, United Kingdom, Monday 6 September 2004. New data from the first international prospective study of statin treatment in people with the metabolic syndrome demonstrate that CRESTOR (rosuvastatin) achieves excellent results in lowering LDL-cholesterol (LDL-C) and raising HDL-C in this important and growing patient population.1 Today's results from the COMETS study, presented at the 40th An...1st data show CRESTOR highly effective at lowering LDL-C in patients with type 2 diabetes
Seville, Spain, Sunday 18 April 2004. New data show CRESTORTM (rosuvastatin) provides superior reductions in a major cardiovascular risk factor, LDL-cholesterol (LDL-C), in patients with type 2 diabetes and dyslipidaemia compared to atorvastatin.1-3 Results from the CORALL study demonstrated that for each dose of CRESTOR, LDL-C was reduced significantly more than with double the dose of atorva...CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
Kyoto, Japan, Monday 29 September 2003. New data presented at the XIIIth International Symposium on Atherosclerosis (ISA) show AstraZeneca's highly effective statin CRESTOR (rosuvastatin) achieves more favourable effects on apolipoprotein and lipid ratios than the same and some higher doses of other widely available statins.1,2 Data also show greater improvements in apolipoprotein and lipid rat...